GT Biopharma Statistics
 Total Valuation
 GT Biopharma has a market cap or net worth of $2.23 million. The enterprise value is -$2.99 million.
 Important Dates
 The next estimated earnings date is Thursday, November 13, 2025, after market close.
 | Earnings Date | Nov 13, 2025 | 
| Ex-Dividend Date | n/a | 
Share Statistics
 GT Biopharma has 3.56 million shares outstanding. The number of shares has increased by 64.62% in one year.
 | Current Share Class | 3.56M | 
| Shares Outstanding | 3.56M | 
| Shares Change (YoY) | +64.62% | 
| Shares Change (QoQ) | +18.19% | 
| Owned by Insiders (%) | 10.99% | 
| Owned by Institutions (%) | 9.57% | 
| Float | 2.18M | 
Valuation Ratios
  | PE Ratio | n/a | 
| Forward PE | n/a | 
| PS Ratio | n/a | 
| Forward PS | n/a | 
| PB Ratio | 0.68 | 
| P/TBV Ratio | 0.78 | 
| P/FCF Ratio | n/a | 
| P/OCF Ratio | n/a | 
| PEG Ratio | n/a | 
 Financial Ratio HistoryEnterprise Valuation
  | EV / Earnings | n/a | 
| EV / Sales | n/a | 
| EV / EBITDA | n/a | 
| EV / EBIT | n/a | 
| EV / FCF | n/a | 
Financial Position
 The company has a current ratio of 3.09
 | Current Ratio | 3.09 | 
| Quick Ratio | 2.27 | 
| Debt / Equity | n/a | 
| Debt / EBITDA | n/a | 
| Debt / FCF | n/a | 
| Interest Coverage | n/a | 
Financial Efficiency
 Return on equity (ROE) is -181.99% and return on invested capital (ROIC) is -130.90%.
 | Return on Equity (ROE) | -181.99% | 
| Return on Assets (ROA) | -82.45% | 
| Return on Invested Capital (ROIC) | -130.90% | 
| Return on Capital Employed (ROCE) | -224.46% | 
| Revenue Per Employee | n/a | 
| Profits Per Employee | -$9.48M | 
| Employee Count | 1 | 
| Asset Turnover | n/a | 
| Inventory Turnover | n/a | 
Taxes
  | Income Tax | n/a | 
| Effective Tax Rate | n/a | 
Stock Price Statistics
 The stock price has decreased by -81.14% in the last 52 weeks. The beta is 1.32, so GT Biopharma's price volatility has been higher than the market average.
 | Beta (5Y) | 1.32 | 
| 52-Week Price Change | -81.14% | 
| 50-Day Moving Average | 0.80 | 
| 200-Day Moving Average | 1.95 | 
| Relative Strength Index (RSI) | 42.00 | 
| Average Volume (20 Days) | 4,495,638 | 
Short Selling Information
 The latest short interest is 1.04 million, so 29.37% of the outstanding shares have been sold short.
 | Short Interest | 1.04M | 
| Short Previous Month | 244,248 | 
| Short % of Shares Out | 29.37% | 
| Short % of Float | 47.84% | 
| Short Ratio (days to cover) | 0.27 | 
Income Statement
  | Revenue | n/a | 
| Gross Profit | n/a | 
| Operating Income | -10.81M | 
| Pretax Income | -9.40M | 
| Net Income | -9.48M | 
| EBITDA | n/a | 
| EBIT | -10.81M | 
| Earnings Per Share (EPS) | -$3.94 | 
 Full Income StatementBalance Sheet
 The company has $5.23 million in cash and n/a in debt, giving a net cash position of $5.23 million or $1.47 per share.
 | Cash & Cash Equivalents | 5.23M | 
| Total Debt | n/a | 
| Net Cash | 5.23M | 
| Net Cash Per Share | $1.47 | 
| Equity (Book Value) | 4.82M | 
| Book Value Per Share | 0.87 | 
| Working Capital | 4.82M | 
 Full Balance SheetCash Flow
  | Operating Cash Flow | -10.42M | 
| Capital Expenditures | n/a | 
| Free Cash Flow | -10.42M | 
| FCF Per Share | -$2.93 | 
 Full Cash Flow StatementMargins
  | Gross Margin | n/a | 
| Operating Margin | n/a | 
| Pretax Margin | n/a | 
| Profit Margin | n/a | 
| EBITDA Margin | n/a | 
| EBIT Margin | n/a | 
| FCF Margin | n/a | 
Dividends & Yields
 GT Biopharma does not appear to pay any dividends at this time.
 | Dividend Per Share | n/a | 
| Dividend Yield | n/a | 
| Dividend Growth (YoY) | n/a | 
| Years of Dividend Growth | n/a | 
| Payout Ratio | n/a | 
| Buyback Yield | -64.62% | 
| Shareholder Yield | -64.62% | 
| Earnings Yield | -424.40% | 
| FCF Yield | -466.52% | 
 Analyst Forecast
 The average price target for GT Biopharma is $11.00, which is 1,651.87% higher than the current price. The consensus rating is "Strong Buy".
 | Price Target | $11.00 | 
| Price Target Difference | 1,651.87% | 
| Analyst Consensus | Strong Buy | 
| Analyst Count | 1 | 
| Revenue Growth Forecast (5Y) | n/a | 
| EPS Growth Forecast (5Y) | n/a | 
 Stock ForecastsFair Value
 There are several formulas that can be used to estimate the intrinsic value of a stock.
 | Lynch Fair Value | n/a | 
| Lynch Upside | n/a | 
| Graham Number | n/a | 
| Graham Upside | n/a | 
Stock Splits
 The last stock split was on February 5, 2024. It was a reverse split with a ratio of 1:30.
 | Last Split Date | Feb 5, 2024 | 
| Split Type | Reverse | 
| Split Ratio | 1:30 | 
Scores
  | Altman Z-Score | n/a | 
| Piotroski F-Score | 1 |